Intravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats

Toxicology and Applied Pharmacology

Volumn 263, Issue 3, 2012, Pages 352-359

  Eyer, Florian ^a   Steimer, Werner ^a   Nitzsche, Thomas ^b,c   Jung, Nicole ^a   Neuberger, Heidi ^a   Müller, Christine ^a   Schlapschy, Martin ^b,c   Zilker, Thomas ^a   Skerra, Arne ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Munich Center for Integrated Protein Science   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anticalin; Antidotal therapy; Digoxin toxicity; Rats

Indexed keywords

ANTICALIN DIGA16; ANTIDOTE; DIGOXIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTOXICATION; ELECTROCARDIOGRAPHY; HEART HEMODYNAMICS; IN VITRO STUDY; MALE; NONHUMAN; RAT; SIMULATION; SURVIVAL RATE;

ANIMALS; ANTIDOTES; CARDIOTONIC AGENTS; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HALF-LIFE; INFUSIONS, INTRAVENOUS; LIPOCALINS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 84865434852     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.07.009     Document Type: Article

References (53)

1. Akera T., Yamamoto S., Chubb J., McNish R., Brody T.M. Biochemical basis for the low sensitivity of the rat heart to digitalis. Naunyn Schmiedebergs Arch. Pharmacol. 1979, 308:81-88.
2. Åkerström B., Borregaard N., Flower D.A., Salier J.-S. Lipocalins 2006, Landes Bioscience, Georgetown, Texas.
3. Axelsson L., Bergenfeldt M., Ohlsson K. Studies of the release and turnover of a human neutrophil lipocalin. Scand. J. Clin. Lab. Invest. 1995, 55:577-588.
4. Azzazy H.M., Duh S.H., Maturen A., Schaller E., Shaw L., Grimaldi R., Shock G., Christenson R.H. Multicenter study of Abbott AxSYM Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors. Clin. Chem. 1997, 43:1635-1640.
5. Bailon P., Won C.Y. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 2009, 6:1-16.
6. Banner W., Bach P., Burk B., Freestone S., Gooch W.M. Influence of assay methods on serum concentrations of digoxin during FAB fragment treatment. J. Toxicol. Clin. Toxicol. 1992, 30:259-267.
7. Barnes B.J., Hollands J.M. Drug-induced arrhythmias. Crit. Care Med. 2010, 38:S188-S197.
8. Bateman D.N. Digoxin-specific antibody fragments: how much and when?. Toxicol. Rev. 2004, 23:135-143.
9. Bazett H.C. An analysis of the time-relations of electrocardiograms. Heart 1920, 7:353-370.
10. Beste G., Schmidt F.S., Stibora T., Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1898-1903.
11. Binder U., Skerra A. Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics. Therapeutic Proteins - Strategies to Modulate Their Plasma Half-lives 2012, 63-80. Wiley-VCH, Weinheim. R. Kontermann (Ed.).
12. Breustedt D.A., Schönfeld D.L., Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta 2006, 1764:161-173.
13. Couillin I., Maillet I., Vargaftig B.B., Jacobs M., Paesen G.C., Nuttall P.A., Lefort J., Moser R., Weston-Davies W., Ryffel B. Arthropod-derived histamine-binding protein prevents murine allergic asthma. J. Immunol. 2004, 173:3281-3286.
14. Cowan S.W., Newcomer M.E., Jones T.A. Crystallographic refinement of human serum retinol binding protein at 2Å resolution. Proteins 1990, 8:44-61.
15. Dasgupta A. Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. Toxicol. Rev. 2006, 25:273-281.
16. Eichinger A., Nasreen A., Kim H.J., Skerra A. Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. J. Biol. Chem. 2007, 282:31068-31075.
17. Eyer F., Jung N., Neuberger H., Schulz R., Steiner K., Ladstetter B., Poethko T., Henke J., Zilker T. Enteral exsorption of acetaminophen after intravenous injection in rats: influence of activated charcoal on this clearance path. Basic Clin. Pharmacol. Toxicol. 2007, 101:163-171.
18. Eyer F., Jung N., Neuberger H., Witte A., Poethko T., Henke J., Zilker T. Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats. Basic Clin. Pharmacol. Toxicol. 2008, 102:337-346.
19. Eyer F., Steimer W., Muller C., Zilker T. Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. Am. J. Crit. Care 2010, 19:387-391.
20. Flanagan R.J., Jones A.L. Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004, 27:1115-1133.
21. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.K. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 2002, 10:1033-1043.
22. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2:256-265.
23. Harrison L.I., Gibaldi M. Pharmacokinetics of digoxin in the rat. Drug Metab. Dispos. 1976, 4:88-93.
24. Harrison L.I., Gibaldi M. Physiologically based pharmacokinetic model for digoxin distribution and elimination in the rat. J. Pharm. Sci. 1977, 66:1138-1142.
25. Hickey A.R., Wenger T.L., Carpenter V.P., Tilson H.H., Hlatky M.A., Furberg C.D., Kirkpatrick C.H., Strauss H.C., Smith T.W. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J. Am. Coll. Cardiol. 1991, 17:590-598.
26. Hursting M.J., Raisys V.A., Opheim K.E., Bell J.L., Trobaugh G.B., Smith T.W. Determination of free digoxin concentrations in serum for monitoring Fab treatment of digoxin overdose. Clin. Chem. 1987, 33:1652-1655.
27. Kelly R.A., Smith T.W. Recognition and management of digitalis toxicity. Am. J. Cardiol. 1992, 69:108G-118G. disc 118G-119G.
28. Kim H.J., Eichinger A., Skerra A. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J. Am. Chem. Soc. 2009, 131:3565-3576.
29. Klaassen C.D. Stimulation of the development of the hepatic excretory mechanism for ouabain in newborn rats with microsomal enzyme inducers. J. Pharmacol. Exp. Ther. 1974, 191:212-218.
30. Korndörfer I.P., Schlehuber S., Skerra A. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J. Mol. Biol. 2003, 330:385-396.
31. +-adenosine triphosphatase and contractile force. J. Pharmacol. Exp. Ther. 1976, 197:458-469.
32. Lechat P., Mudgett-Hunter M., Margolies M.N., Haber E., Smith T.W. Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. J. Pharmacol. Exp. Ther. 1984, 229:210-213.
33. Li W., Mase M., Inui T., Shimoda M., Isomura K., Oda H., Yamada K., Urade Y. Pharmacokinetics of recombinant human lipocalin-type prostaglandin D synthase/beta-trace in canine. Neurosci. Res. 2008, 61:289-293.
34. Maitai C.K., Njoroge D.K., Munenge R.W. Interaction between nifedipine and digoxin in rats. East Afr. Med. J. 1995, 72:75-76.
35. Mross K., Fischer R., Richly H., Scharr D., Buechert M., Stern A., Hoth D., Gille H., Audoly L.P., Scheulen M.E. First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: results of a dose escalation study. Mol. Cancer Ther. 2011, 10:A212.
36. 1-acid glycoprotein genetic variants, the A and F1*S forms. J. Biol. Chem. 2011, 286:14427-14434.
37. Ordog G.J., Benaron S., Bhasin V., Wasserberger J., Balasubramanium S. Serum digoxin levels and mortality in 5,100 patients. Ann. Emerg. Med. 1987, 16:32-39.
38. Oubaassine R., Bilbault P., Roegel J.C., Alexandre E., Sigrist S., Lavaux T., Jaeger A., Pinget M., Kessler L. Cardio protective effect of glucose-insulin infusion on acute digoxin toxicity in rat. Toxicology 2006, 224:238-243.
39. Putterman C., Ben-Chetrit E., Caraco Y., Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin. Arthritis Rheum. 1991, 21:143-155.
40. Rask L., Anundi H., Bohme J., Eriksson U., Fredriksson A., Nilsson S.F., Ronne H., Vahlquist A., Peterson P.A. The retinol-binding protein. Scand. J. Clin. Lab. Invest. Suppl. 1980, 154:45-61.
41. Schlapschy M., Theobald I., Mack H., Schottelius M., Wester H.J., Skerra A. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng. Des. Sel. 2007, 20:273-284.
42. Schlehuber S., Beste G., Skerra A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 2000, 297:1105-1120.
43. Schlehuber S., Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". Drug Discov. Today 2005, 10:23-33.
44. Schmidt T.G., Skerra A. The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat. Protoc. 2007, 2:1528-1535.
45. Schönfeld D., Matschiner G., Chatwell L., Trentmann S., Gille H., Hülsmeyer M., Brown N., Kaye P.M., Schlehuber S., Hohlbaum A.M., Skerra A. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8198-8203.
46. Skerra A. Lipocalins as a scaffold. Biochim. Biophys. Acta 2000, 1482:337-350.
47. Skerra A. Imitating the humoral immune response. Curr. Opin. Chem. Biol. 2003, 7:683-693.
48. Skubitz K.M., O'Hara D.S., Smith T.W. Antibody-hapten reaction kinetics: a comparison of hapten interactions with IgG and Fab preparations. J. Immunol. 1977, 118:1971-1976.
49. Smith T.W., Lloyd B.L., Spicer N., Haber E. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin. Exp. Immunol. 1979, 36:384-396.
50. Spoerke D.G., Rumack B.H.E. Handbook of Mushroom Poisoning: Diagnosis and Treatment 1994, CRC Press, Boca Raton, FL.
51. Stone J.A., Soldin S.J. An update on digoxin. Clin. Chem. 1989, 35:1326-1331.
52. Tarlo S.M., Shaikh W., Bell B., Cuff M., Davies G.M., Dolovich J., Hargreave F.E. Papain-induced allergic reactions. Clin. Allergy 1978, 8:207-215.
53. Weinhouse E., Kaplanski J., Posner J. Comparison of digoxin-induced cardiac toxicity in resistant and sensitive species. J. Pharm. Pharmacol. 1983, 35:580-583.